|
Delayed
NSE India S.E.
10:27:49 29/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 351.90 INR | +0.34% |
|
+6.54% | -10.66% |
| 10-26 | Biocon Signs License Agreement to Commercialize Stelara Biosimilar in Nine Markets | MT |
| 10-15 | Biocon Chair: AI in Clinical Trials Is the Holy Grail | MT |
| Market Cap | 571B 6B 5.38B 4.97B 4.5B 8.42B 8.52B 59.46B 23.69B 299B 22.5B 22.02B 949B | P/E 2027 * |
52.3x | P/E 2028 * | 30.8x |
|---|---|---|---|---|---|
| Enterprise Value | 674B 7.07B 6.35B 5.87B 5.31B 9.93B 10.05B 70.16B 27.94B 353B 26.55B 25.99B 1,119B | EV / Sales 2027 * |
3.47x | EV / Sales 2028 * | 2.97x |
| Free-Float |
51.78% | Yield 2027 * |
0.16% | Yield 2028 * | 0.23% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| BIOCON | Delayed | |
Bombay S.E.
| BIOCON | Delayed |
Last Transcript: Biocon Limited
| 1 day | +0.34% | ||
| 1 week | +6.54% | ||
| Current month | -4.97% | ||
| 1 month | -6.66% | ||
| 3 months | -18.37% | ||
| 6 months | -2.86% | ||
| Current year | -10.66% |
| 1 week | 318.4 |  | 357.3 |
| 1 month | 318.4 | | 381.2 |
| Current year | 318.4 | | 447.15 |
| 1 year | 318.4 | | 447.15 |
| 3 years | 217.5 | | 447.15 |
| 5 years | 191.55 | | 447.15 |
| 10 years | 134.07 | | 487.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
Saurabh Paliwal
IRC | Investor Relations Contact | - | - |
Shreehas Tambe
CEO | Chief Executive Officer | - | 31/03/2026 |
Kedar Upadhye
DFI | Director of Finance/CFO | 48 | 31/03/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 23/04/2014 | |
| Director/Board Member | 71 | 31/12/1999 | |
| Chairman | 73 | 28/11/1978 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.34% | +6.54% | -5.83% | +58.58% | 6B | |
| +0.65% | -3.36% | +36.98% | +60.50% | 64.14B | |
| +1.33% | +3.04% | +12.64% | +84.55% | 55.53B | |
| +1.22% | +1.40% | +12.62% | +104.49% | 53.03B | |
| +2.76% | +0.87% | +27.92% | +55.07% | 45.99B | |
| +2.00% | -3.39% | +17.83% | +119.04% | 42.45B | |
| +1.34% | -2.86% | +224.43% | +914.08% | 40.45B | |
| +0.64% | -3.95% | +11.15% | +45.57% | 32.25B | |
| -1.98% | +42.16% | +102.96% | +89.50% | 34.47B | |
| -2.72% | -0.44% | +23.18% | -10.77% | 24.23B | |
| Average | +0.56% | +4.14% | +46.39% | +152.06% | 39.85B | |
| Weighted average by Cap. | +0.84% | +3.51% | +48.42% | +158.89% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 194B 2.04B 1.83B 1.69B 1.53B 2.86B 2.89B 20.2B 8.05B 102B 7.64B 7.48B 322B | 223B 2.34B 2.1B 1.94B 1.76B 3.28B 3.32B 23.19B 9.24B 117B 8.78B 8.59B 370B |
| Net income | 10.97B 115M 103M 95.53M 86.51M 162M 164M 1.14B 455M 5.74B 432M 423M 18.22B | 17.97B 189M 169M 156M 142M 265M 268M 1.87B 745M 9.4B 708M 693M 29.84B |
| Net Debt | 103B 1.08B 967M 894M 810M 1.51B 1.53B 10.69B 4.26B 53.74B 4.05B 3.96B 171B | 90.59B 951M 853M 789M 715M 1.33B 1.35B 9.43B 3.76B 47.4B 3.57B 3.49B 150B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/10/26 | ₹351.90 | +0.34% | 3,113,378 |
| 28/10/26 | ₹350.70 | +5.49% | 4,259,637 |
| 27/10/26 | ₹332.45 | +1.11% | 3,040,821 |
| 26/10/26 | ₹328.80 | +1.64% | 3,058,458 |
| 23/10/26 | ₹323.50 | -2.06% | 3,471,319 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BIOCON Stock
Select your edition
All financial news and data tailored to specific country editions
